EFFICACY OF ATORVASTATIN IN REDUCING PROTEINURIA IN PATIENTS OF CHRONIC KIDNEY DISEASE

Código QR

EFFICACY OF ATORVASTATIN IN REDUCING PROTEINURIA IN PATIENTS OF CHRONIC KIDNEY DISEASE

Objective: To determine the efficacy of atorvastatin in reducing proteinuria in patients of chronic kidney disease. Study Design: Quasi experimental study. Place and Duration of Study: Combined Military Hospital Multan, from Jan 2014 to Jun 2014. Material and Methods: Seventy patients of bo...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Rizwan Azam, Ejaz Ahmed, Asad Raza, Mahwish Rizwan, Ali Jamal, Syed Salman Ali
Formato:	article
Lenguaje:	EN
Publicado:	Army Medical College Rawalpindi 2019
Materias:	atorvastatin chronic kidney disease efficacy Medicine R Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/e114ee44175f46adb5e160ccc7fb473d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Atorvastatin Has no Effects on Kidney Tissues of Wistar Albino Rats in the Long-Term Intake: An Electron Microscopic Study
por: Aktas,Ayfer, et al.
Publicado: (2011)

FREQUENCY AND CORRELATES OF MYOPATHY IN PATIENTS WITH DIABETES TAKING ATORVASTATIN
por: Kamil Rehman Butt, et al.
Publicado: (2021)

Atorvastatin-Medicated Dentifrice Significantly Inhibits CD4+ T Cell Proliferation: In vitro Pilot Study
por: Rosenberg,David R, et al.
Publicado: (2017)

Chitosan-Coated PLGA Nanoparticles for Enhanced Ocular Anti-Inflammatory Efficacy of Atorvastatin Calcium
por: Arafa MG, et al.
Publicado: (2020)

STABILITY-INDICATING RP-HPLC METHOD FOR ANALYSIS OF ATORVASTATIN IN BULK DRUG, MARKETED TABLET AND NANOEMULSION FORMULATION
por: MUSTAFA,GULAM, et al.
Publicado: (2010)

A VALIDATED DENSITOMETRIC METHOD FOR ANALYSIS OF TELMISARTAN AND ATORVASTATIN CALCIUM IN FIXED DOSE COMBINATION
por: PATIL,U. P, et al.
Publicado: (2010)

Synergistic effects of liposomes encapsulating atorvastatin calcium and curcumin and targeting dysfunctional endothelial cells in reducing atherosclerosis
por: Li X, et al.
Publicado: (2019)

Potential Effect of Curcumin versus Atorvastatin on Hepatic and Metabolic Changes in Rat Model of Metabolic Syndrome
por: Alaaeldin Eissa, et al.
Publicado: (2021)

COMPARISON OF LIPID LOWERING EFFECTS OF ROSUVASTATIN AND ATORVASTATIN IN TYPE 2 DIABETIC PATIENTS WITH PRIMARY HYPERLIPIDEMIA
por: Safina Shabbir, et al.
Publicado: (2020)

EFFECTS OF AN EIGHT-WEEK ATORVASTATIN TREATMENT ON SPONTANEOUS CYTOKINE PRODUCTION BY THE BLOOD MONONUCLEAR LEUKOCYTES IN METABOLIC SYNDROME
por: I. D. Bespalovа, et al.
Publicado: (2014)

A pharmacokinetics‐based approach to the monitoring of patient adherence to atorvastatin therapy
por: Gellért Balázs Karvaly, et al.
Publicado: (2021)

Simultaneous administration of high-dose atorvastatin and clopidogrel does not interfere with platelet inhibition during percutaneous coronary intervention
por: Kreutz RP, et al.
Publicado: (2016)

Chronic Intractable Pruritus in Chronic Kidney Disease Patients: Prevalence, Impact, and Management Challenges — A Narrative Review
por: Świerczyńska K, et al.
Publicado: (2021)

Simple spectrophotometric methods for the determination of amlodipine and atorvastatin in bulk and tablets
por: Imad Osman Abu Reid, et al.
Publicado: (2021)

Liquisolid Tablets Formulation of Atorvastatin Calcium Using Polyethylene Glycol 400 as Solvent and Some Carrier Materials
por: Yulias Ninik Windriyati, et al.
Publicado: (2020)

Chronic Kidney Disease Related Anemia- A Narrative Review
por: Martina Hrvačić, et al.
Publicado: (2021)

Calcium and phosphorus parameters and their association with serum parathormone in chronic kidney patients on hemodialysis
por: Mendes,Vitória Ribeiro, et al.
Publicado: (2021)

Cardiovascular Safety of Anti-Sclerostin Therapy in Chronic Kidney Disease
por: Daniel Cejka
Publicado: (2021)

High Unawareness of Chronic Kidney Disease in Germany
por: Susanne Stolpe, et al.
Publicado: (2021)

COMPARATIVE EFFICACY OF ORAL FLUCONAZOLE AND ORAL ITRACONAZOLE IN PITYRIASIS VERSICOLOR
por: Muhammad Rizwan, et al.
Publicado: (2021)

Cholemic Nephropathy as Cause of Acute and Chronic Kidney Disease. Update on an Under-Diagnosed Disease
por: Francesca Tinti, et al.
Publicado: (2021)

Atorvastatin attenuates the production of IL-1β, IL-6, and TNF-α in the hippocampus of an amyloid β1-42-induced rat model of Alzheimer’s disease
por: Zhang YY, et al.
Publicado: (2013)

A Comparison on Effects of High Dose Rosuvastatin versus High Dose Atorvastatin on Lipid Profile and CRP Level in Patients Undergoing Percutaneous Coronary Intervention: A Randomized Study
por: Mahboubeh Darban, et al.
Publicado: (2021)

Serum Interleukin-17 Alterations in Patients With Chronic Kidney Disease Undergoing Eight Weeks of Aerobic Training
por: Arman Jalili, et al.
Publicado: (2021)

Risk of kidney health among returnee Nepali migrant workers: A survey of nephrologists
por: Nirmal Aryal, et al.
Publicado: (2021)

Exogenous Wnt1 Prevents Acute Kidney Injury and Its Subsequent Progression to Chronic Kidney Disease
por: Xue Hong, et al.
Publicado: (2021)

Atorvastatin Regulates MALAT1/miR-200c/NRF2 Activity to Protect Against Podocyte Pyroptosis Induced by High Glucose
por: Zuo Y, et al.
Publicado: (2021)

A clinical case of new onset type 2 diabetes mellitus in a patient with coronary artery disease and obesity treated with atorvastatin
por: T.A. Maksymets, et al.
Publicado: (2018)

La atorvastatina no modifica el incremento agudo de los niveles de p-selectina y fibrinógeno inducido con esfuerzo físico máximo
por: Lindefjeld,Dante, et al.
Publicado: (2010)

Asociación de niveles de lípidos y haplogrupos Amerindios de DNA mitocondrial en individuos chilenos hipercolesterolémicos tratados con Atorvastatina
por: Lagos,Jenny, et al.
Publicado: (2010)

Optimization of Timing and Times for Administration of Atorvastatin‐Pretreated Mesenchymal Stem Cells in a Preclinical Model of Acute Myocardial Infarction
por: Jun Xu, et al.
Publicado: (2019)

EFFECT OF SUBCUTANEOUS RECOMBINANT HUMAN ERYTHROPOIETIN ON BLOOD PRESSURE IN PRE-DIALYSIS CHRONIC KIDNEY DISEASE (CKD) PATIENTS
por: Muhammad Sajid Hussain, et al.
Publicado: (2021)

Editorial: Nutritional Aspects of Kidney Disease
por: Alice Sabatino, et al.
Publicado: (2021)

Current and emerging treatment options for the elderly patient with chronic kidney disease
por: Fassett RG
Publicado: (2014)

Perfluoroalkyl substances and kidney function in chronic kidney disease, anemia, and diabetes
por: Conway BN, et al.
Publicado: (2018)

The prevalence of depression and the association between depression and kidney function and health-related quality of life in elderly patients with chronic kidney disease: a multicenter cross-sectional study
por: Wang WL, et al.
Publicado: (2019)

Bone Marrow Hypocellularity in Patients with End-Stage Kidney Disease
por: Chia-Chen Hsieh, et al.
Publicado: (2021)

Role of asymptomatic hyperuricemia in the progression of chronic kidney disease and cardiovascular disease
por: Yousuf Waheed, et al.
Publicado: (2021)

Efficacy of Low-Dose Trimethoprim/Sulfamethoxazole for the Treatment of Pneumocystis jirovecii Pneumonia in Deceased Donor Kidney Recipients
por: Ji J, et al.
Publicado: (2021)

Evaluation of adductor pollicis muscle thickness obtained by ultrasonography and adipometer in patients with chronic kidney disease under conservative treatment
por: Pereira,Priscila, et al.
Publicado: (2020)